Yungjin Pharm is attending the 2019 BIO International Convention at Philadelphia, and featuring the company presentation for on-going development pipelines. 

The BIO International Convention is one of the biggest exhibition and partnering event worldwide, which brings together over 18,000 attendees from global bio-technologies, pharmaceutical companies, CRO and CMO to get together for networking opportunities.

Yungjin had made a presentation and one-on-one partnering meetings for YPL-001 (COPD treatment), a core pipeline completes phase 2a clinical study in US, and YPN-005, a candidate oncology pipeline targeting CDK7 inhibitor.

In early April, YPN-005 was presented the inhibition effect of cancer cell growth and oncogene expression at the American Association for Cancer Research (AACR)2019. In addition, YPN-005 was selected as a new drug development project by KDDF (Korea Drug Development Fund), and  will enter into a step for preclinical toxicity study within second half of this year.